Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA)

Sumoza, Abraham; Bisotti, Renate de; Sumoza, David; Fairbanks, Virgil F.

doi:10.1002/ajh.10205

Cited by 64 publications

(52 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,[7][8][9][10] Baseado nisso foi elaborado um protocolo de uso de HU para os pacientes portadores de SF do Hospital Hemope, obedecendo aos critérios já comentados na metodologia.…”

Section: Discussionunclassified

“…7 Ao longo dos anos, estudos em crianças têm demonstrado igual eficácia de HU sem grandes efeitos colaterais. 2,7,8,9,10 Assim, o presente estudo teve como objetivos, a partir de uma série de casos, investigar a eficácia e a tolerabilidade ao uso de HU por pacientes portadores de SF nas faixas etárias pediátrica e adultos jovens, bem como avaliar variações de parâmetros hematológicos em ambos os grupos etários e dos valores da Hb F, no grupo pediátrico.…”

Section: Introductionunclassified

See 1 more Smart Citation

Hidroxiuréia em pacientes com síndromes falciformes acompanhados no Hospital Hemope, Recife, Brasil

Bandeira¹,

Peres²,

Carvalho³

et al. 2004

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

“…2,[7][8][9][10] Baseado nisso foi elaborado um protocolo de uso de HU para os pacientes portadores de SF do Hospital Hemope, obedecendo aos critérios já comentados na metodologia.…”

Section: Discussionunclassified

Section: Introductionunclassified

Hidroxiuréia em pacientes com síndromes falciformes acompanhados no Hospital Hemope, Recife, Brasil

Bandeira¹,

Peres²,

Carvalho³

et al. 2004

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

“…18 In 5 of our patients, chronic transfusion has been continued for at least 3 months after the start of HU, and this might explain why they did not experience early recurrence. In another cohort of 5 patients, 19 HU was effective at preventing recurrent stroke. Our results, as well as those described by Ware et al 18 and Sumoza et al, 19 suggest that chronic transfusion might be safely stopped after the start of HU therapy and that HU may prevent stroke recurrence when chronic transfusion is not possible.…”

Section: Discussionmentioning

confidence: 99%

“…In another cohort of 5 patients, 19 HU was effective at preventing recurrent stroke. Our results, as well as those described by Ware et al 18 and Sumoza et al, 19 suggest that chronic transfusion might be safely stopped after the start of HU therapy and that HU may prevent stroke recurrence when chronic transfusion is not possible.…”

Section: Discussionmentioning

confidence: 99%

Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience

Gulbis¹

2005

Blood

148

103

View full text Add to dashboard Cite

Hydroxyurea (HU) is considered to be the most successful drug therapy for severe sickle cell disease (SCD). Nevertheless, questions remain regarding its benefits in very young children and its role in the prevention of cerebrovascular events. There were 127 SCD patients treated with no attempt to reach maximal tolerated doses who entered the Belgian Registry: 109 for standard criteria and 18 who were at risk of stroke only. During 426 patientyears of follow-up for patients with standard criteria, 3.3 acute chest syndromes, 1.3 cerebrovascular events, and 1.1 osteonecrosis per 100 patient-years were observed. A subgroup of 32 patients followed for 6 years experienced significant benefit over this period. In each subgroup of children (younger than 2 years, 2-5, 6-9, and 10-19 years) followed for 2 years, clinical and biologic changes were similar, except for children younger than 2 years who had no total hemoglobin increase and remained at risk of severe anemia. In 72 patients evaluated by transcranial Doppler studies (TCD), 34 patients were at risk of primary stroke and only 1 had a cerebrovascular event after a follow-up of 96 patient-years. These results confirm the benefit of HU, even in very young children, and its possible role in primary stroke prevention. (Blood. 2005; 105:2685-2690)

show abstract

“…126 Hydroxyurea therapy may also prevent stroke in SCD. 127 Nocturnal oxygen saturation inversely correlated with risk of cerebral ischemic events and nocturnal oxygen supplementation may be an additional opportunity for intervention. 128 Treatment of moya moya disease (MMD) presents unique challenges and controversies.…”

Section: Disease-specific Therapiesmentioning

confidence: 99%

Therapeutic approaches and advances in pediatric stroke

Kirton

deVeber

2006

NeuroRX

View full text Add to dashboard Cite

Summary:Evidence-based therapeutic interventions for pediatric ischemic cerebrovascular disease are beginning to emerge. The primary therapeutic target is usually the pathological prothrombotic disturbance that underlies the majority of pediatric stroke. A battle between anticoagulation and anti-platelet therapies continues to provide controversy and is the inspiration for upcoming randomized trials. Supportive care and neuroprotective strategies are an important consideration in children with stroke. Attempts to determine the safety of acute thrombolytic interventions are also underway. Finally, unique medical and surgical treatments for specific diseases leading to stroke in children continue to evolve. After briefly summarizing the epidemiology, pathophysiology, diagnosis, and outcomes of ischemic strokes in children, treatment approaches and alternatives will be reviewed in detail with emphasis placed on current areas of controversy and future directions for clinical research.

show abstract

Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA)

Cited by 64 publications

References 27 publications

Hidroxiuréia em pacientes com síndromes falciformes acompanhados no Hospital Hemope, Recife, Brasil

Hidroxiuréia em pacientes com síndromes falciformes acompanhados no Hospital Hemope, Recife, Brasil

Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience

Therapeutic approaches and advances in pediatric stroke

Contact Info

Product

Resources

About